Startups

Tucuvi: $20 Million Series A Raised To Scale AI Care Management Platform

By Amit Chowdhry ● Jan 10, 2026

Tucuvi has raised $20 million in Series A funding to accelerate adoption of its AI Care Management platform across healthcare organizations, as systems grapple with workforce shortages, rising demand, and increasing operational complexity. The round was co-led by Cathay Innovation and Kfund through its early-growth fund Leadwind, with participation from existing investors Frontline Ventures, Seaya Ventures, and Shilling.

bit.bio Raises $50 Million Series C Led by M&G To Scale Human Cell Programming Platform

By Amit Chowdhry ● Jan 10, 2026

M&G Investments has led a $50 million Series C funding round for bit.bio, a Cambridge-based biotechnology company developing human cell programming technology to improve the speed and predictability of drug discovery and safety testing.

Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma

By Amit Chowdhry ● Jan 10, 2026

Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development of frevecitinib, its lead inhaled anti-inflammatory candidate for severe asthma and other serious respiratory diseases. The round was led by new investors RA Capital Management and Forge Life Science Partners, with participation from EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, and Sixty Degree Capital, alongside existing backers Atlas Venture, 5AM Ventures, and Gimv.

Rain: $250 Million Series C At $1.95 Billion Valuation Raised To Expand Stablecoin Payments Platform

By Amit Chowdhry ● Jan 10, 2026

Rain, which provides enterprise infrastructure for stablecoin-powered payments, has raised a $250 million Series C round led by ICONIQ, valuing the company at $1.95 billion. The financing brings Rain’s total funding to more than $338 million, and follows its Series B by about four months and its Series A by about 10 months.

Carna Health: $8 Million Raised To Expand Global Chronic Kidney Disease Screening Platform

By Amit Chowdhry ● Jan 10, 2026

Carna Health announced it has raised $8 million to expand global access to its chronic kidney disease screening and care management technology, following a strategic partnership with Siemens Healthineers to scale preventive kidney care worldwide.

Hadrian Raises Funding At $1.6 Billion Valuation To Scale New U.S. Factories

By Amit Chowdhry ● Jan 10, 2026

Hadrian, a company focused on building advanced U.S. manufacturing capacity for aerospace, defense, and critical infrastructure, announced it has raised expanded capital led by accounts advised by T. Rowe Price Associates. The financing values the company at $1.6 billion, Hadrian said.

Vizgen: $48 Million Funding Raised To Scale Spatial Multi-Omics Platform

By Amit Chowdhry ● Jan 10, 2026

Vizgen, a spatial multi-omics company, announced it has closed a $48 million financing led by ARCH Venture Partners and co-led by M Ventures and Northpond Ventures, with participation from existing investors.

Enhanced Digital Group: Series A Funding Raised For Expanding Institutional Crypto Derivatives Offering

By Amit Chowdhry ● Jan 10, 2026

Enhanced Digital Group (EDG), a provider of digital asset derivatives solutions, said StoneX Digital, a division of StoneX Group Inc. (Nasdaq: SNEX), led its Series A financing round.

Abbelight: Series B Raised To Expand Super-Resolution Microscopy Adoption

By Amit Chowdhry ● Jan 10, 2026

Abbelight announced it has closed a Series B financing round led by AVANT BIO, as the Paris-based company looks to accelerate product innovation and broaden commercial adoption of its super-resolution microscopy solutions across a wider customer base.

EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline

By Amit Chowdhry ● Jan 10, 2026

EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and Johnson & Johnson, through Johnson & Johnson Innovation – JJDC, with participation from new and existing investors.

32 Biosciences: $40M Series A Launched To Advance GI Mucosal-Immune Therapeutics

By Amit Chowdhry ● Jan 10, 2026

32 Biosciences, a gastrointestinal-focused biotechnology company, announced it will launch a $40 million Series A financing during the 2026 J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12–15, 2026.

BrightHeart: €11 Million Series A Raised To Expand Prenatal Ultrasound AI Platform

By Amit Chowdhry ● Jan 10, 2026

BrightHeart, a Paris-based developer of AI software for prenatal ultrasound, said it has closed an €11 million Series A financing to fund U.S. commercialization, broader European expansion and continued product development for its B-Right AI Platform.

Luxury Presence: $37 Million Raised To Advance Presence CRM, An AI Relationship Engine For Real Estate Agents

By Amit Chowdhry ● Jan 10, 2026

Luxury Presence, a growth platform used by more than 87,000 residential real estate agents and brands, announced it raised $37 million in new capital to accelerate the development and launch of Presence CRM, which it is positioning as an AI-driven system designed to surface deal opportunities from an agent’s existing network.

Enodia Therapeutics: €20.7 Million Seed Funding Closed To Advance SEC61-Based Small-Molecule Protein Degradation Platform

By Amit Chowdhry ● Jan 10, 2026

Enodia Therapeutics has raised €20.7 million (about $25 million) in a seed financing to advance a discovery platform that uses proteomics and machine learning to develop small molecules that degrade disease-driving proteins at the point of synthesis. The round was co-led by Elaia, Pfizer Ventures, and Bpifrance as part of its InnoBio investment strategy, with participation from Wallonie Entreprendre, Argobio Studio, MACSF, The Institut Pasteur, InvestSud, Sambrinvest, and Mission BioCapital.

SonoThera: $125 Million Series B Raised To Advance Ultrasound-Mediated Genetic Medicines Toward First-In-Human Trials

By Amit Chowdhry ● Jan 10, 2026

SonoThera announced it will officially launch a $125 million Series B funding round at the 44th annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12–15, 2026, as the company looks to advance multiple genetic medicine programs toward first-in-human studies.

Engitix: $25 Million Series A Extension Closed To Advance ECM-Targeted Pipeline In Oncology and Fibrosis

By Amit Chowdhry ● Jan 9, 2026

Engitix Therapeutics announced it has closed a $25 million Series A extension financing led by Netherton Investments, a fund investing on behalf of Mike Platt, co-founder and managing director of BlueCrest Capital Management.

Argobio Launches Enodia With €20.7 Million Seed Round To Develop Small Molecules For Protein Degradation

By Amit Chowdhry ● Jan 9, 2026

Argobio Studio announced it has launched Enodia Therapeutics and completed a €20.7 million ($25 million) seed financing to advance a small-molecule platform for targeted protein degradation at the point of protein synthesis, enabled by proteomics and machine learning.

Haveli Investments To Take Majority Stake In Sirion

By Amit Chowdhry ● Jan 9, 2026

Sirion, a contract lifecycle management (CLM) software provider, announced it has signed a definitive agreement for Haveli Investments, an Austin-based technology-focused investment firm, to make a majority investment in the company.

KAHR Bio: $22 Million Raised And Phase 2 Topline Data For DSP107 Combo In MSS Colorectal Cancer

By Amit Chowdhry ● Jan 9, 2026

KAHR Bio announced it posted “strong” topline results from a Phase 2a dose-expansion cohort evaluating its investigational immunotherapy DSP107 in combination with Roche’s atezolizumab (Tecentriq) in late-line metastatic microsatellite stable colorectal cancer (MSS-CRC), a setting where checkpoint inhibitors have historically shown limited benefit.

Pomelo Care: $92 Million Series C At $1.7B Valuation Closed To Expand Beyond Maternity

By Amit Chowdhry ● Jan 9, 2026

Pomelo Care announced it raised $92 million in Series C funding at a $1.7 billion valuation as it moves to broaden its virtual, evidence-based care model beyond maternity into a wider set of women’s and children’s health needs across the lifespan.

Flywheel Raises $27.5 Million And Expands Clinical Trial And Medical Device Offerings

By Amit Chowdhry ● Jan 9, 2026

Flywheel, a medical imaging data management and analysis platform, reported record momentum in 2025, launched new products aimed at clinical trial and medical device workflows, and disclosed the close of a $27.5 million equity financing round.

Valinor Enterprises: $54 Million Series A Raised To Expand Defense-Tech Holding Company Model

By Amit Chowdhry ● Jan 9, 2026

Valinor Enterprises, an operational holding company focused on defense and government technology, said it raised $54 million in Series A financing, bringing total capital raised to more than $85 million. The round was led by Friends & Family Capital, a venture firm co-founded by former Palantir CFO Colin Anderson and investor John Fogelsong. Existing backers General Catalyst, Founders Fund, and Red Cell Partners also participated, while new investors included Narya, XYZ Venture Capital, and Fifth Down Capital.

AgileRL Raises Seed Round To Launch Arena RLOps Platform In The U.S.

By Amit Chowdhry ● Jan 8, 2026

AgileRL has raised a seed financing round backed by Fusion Fund and Flying Fish, with participation from existing investors Octopus Ventures and Counterview Capital, bringing the company’s total funding raised to $7.5 million.

Prudentia Sciences: $20 Million Series A Raised To Speed Life Sciences Deal Diligence

By Amit Chowdhry ● Jan 8, 2026

Prudentia Sciences announced it raised $20 million in Series A financing to expand its AI-native due diligence platform for life sciences dealmaking, aiming to help pharmaceutical companies, biotechs, and financial institutions evaluate therapeutic assets faster and with more rigor.

Luminate: $21 Million Series A Extension Closed To Scale At-Home Cancer Infusions And Patient-Led Delivery Technology

By Amit Chowdhry ● Jan 8, 2026

Luminate, a Galway, Ireland-based healthcare technology company focused on delivering cancer therapies in the home, has raised $21 million in an expanded Series A round, bringing total funding to more than $50 million. The round was co-led by ARTIS Ventures and Lachy Groom, with participation from Western Alliance Life Sciences and existing backers including 8VC, Y Combinator, Atlantic Bridge, Faber, SciFounders, and others. The company said the financing follows growing interest from health systems in its Lotus program for home-based cancer care.

Redgate Software Secures Growth Investment From Bregal Sagemount

By Amit Chowdhry ● Jan 8, 2026

Redgate Software announced it has received a strategic growth investment from Bregal Sagemount, a growth-focused private equity firm, in a transaction that will make Sagemount the majority shareholder of Redgate, pending regulatory approvals and customary closing conditions. Financial terms were not disclosed, and the companies said the deal is expected to close in late Q1 2026.

ATG Emerges From Stealth With $15 Million To Build An AI-Based Financial Advisor

By Amit Chowdhry ● Jan 8, 2026

Autonomous Technologies Group (ATG) announced it has emerged from stealth as an AI research lab focused on building an advanced AI financial advisor, positioning its flagship product, Autonomous, as a personalized investment strategist that combines market data, portfolio theory, behavioral finance, and user context to guide investment decisions.

Poplar Therapeutics Launched With $50 Million Series A To Advance Anti-IgE Therapy for Multiple Atopic Conditions

By Amit Chowdhry ● Jan 8, 2026

Poplar Therapeutics has launched as a clinical-stage immunology company with a $50 million Series A financing to advance PHB-050, a next-generation anti-IgE antibody being developed for food allergy and other atopic conditions such as asthma and atopic dermatitis.

IMVARIA Announces Strategic Investments For AI-Based Digital Biomarker Solutions

By Amit Chowdhry ● Jan 8, 2026

IMVARIA, a Berkeley, California-based health tech company developing AI-driven digital biomarker solutions, said it has secured strategic investments from new and existing investors to accelerate growth and expand its AI-powered diagnostic services.

Corsera Health: $80 Million Series A Raised To Advance Cardiovascular Disease Prediction

By Amit Chowdhry ● Jan 8, 2026

Corsera Health announced it raised an oversubscribed $80 million Series A to advance its cardiovascular disease prediction-and-prevention strategy and to fund development of once-annual preventive RNAi medicines targeting the two primary drivers of atherosclerotic cardiovascular disease (ASCVD): elevated LDL cholesterol and high blood pressure. The round was co-led by Forbion and Population Health Partners, with participation from additional investors including Corsera co-founder and co-CEO John Maraganore, Ph.D. As part of the financing, Forbion general partner Marco Boorsma, Ph.D., will join Corsera’s board.